Summary

The biotechnology reagents market is expected to register a CAGR of nearly 7.4% over the forecast period.

In the context of COVID-19, government organizations in various countries, research institutes, and many biotech and pharmaceutical firms are focusing on effective and rapid technologies for the fast diagnosis of COVID-19 and developing vaccines/new therapeutics to overcome the current situation. Hence, there is a huge demand for biotechnology reagents during the COVID-19 pandemic, which, in turn, is driving the market growth. For instance, in March 2020, the German Federal Ministry of Education and Research (BMBF) committed EUR 145 million of immediate funding to the Coalition for Epidemic Preparedness Innovations (CEPI) and to support the development of a vaccine against COVID-19.

Certain factors driving the market growth include high R&D expenditure by biotechnology companies, increasing interest in stem cell research, and a rise in the number of biotechnology firms.

The drug manufacturing companies have initiated stem cell research, and several players in the pharmaceutical industry are using these cells to test the toxicity of drugs, which helps them to identify new therapies. As per the Australian Government Department of Health 2019, the stem cell therapies mission was launched by the Government of Australia. It is a research funding program with an investment of around USD 150 million over nine years to develop innovative, safe, and effective treatments for patients suffering from incurable diseases.

Much of the investments for stem cell research go into reagents, as their characterization and modification, along with tools for assessment of stem cell discoveries, play the primary role. There are several companies in the market that specializes only in the development of reagents, which can be useful for cell-line experiments and related discoveries.

Moreover, increasing funding for biotechnology research and the growing number of biotech startups are also major factors driving the market. For instance, In May 2020, Nautilus Biotechnology has raised USD 76 million series B funding from Vulcan Capital to accelerate the development of to bring a next-generation, single-molecule platform for analyzing and quantifying the human proteome.

However, the high cost of reagents, coupled with stringent government regulations for approval of reagents, is the major factor restraining the biotechnology reagents market.

Key Market Trends

The Polymerase Chain Reaction (PCR) Segment is Expected to Hold Significant Market Share

Polymerase chain reaction (PCR) is a technique that amplifies the amount of target nucleic acid in every cycle. It is a technique that is used to amplify target DNA and generate thousands to millions of copies of a particular DNA segment. ​PCR techniques are used in clinical and research laboratories for a wide variety of applications, which include clinical diagnosis, criminal forensics, and biomedical research. ​

PCR-based techniques have mostly been used for pre-screening analysis. PCR-based methods, like single-stranded conformation polymorphism (SSCP) analysis and Amplified fragment length polymorphism (AFLP), have been routinely used in labs to screen for various chronic and infectious diseases. ​

Biotechnology reagents used in PCR techniques are engineered and designed for performing PCR reactions and controlled polymerase activities. As the application of PCR techniques is expanding to vast areas, developments in PCR reagents have followed suit. Different types of reagents used in PCR techniques include NA/RNA template, DNA polymerase, primers (forward and reverse), deoxynucleotide triphosphates (dNTPs), and PCR buffers.

Moreover, market players are continuously launching new products to gain a competitive advantage in the market. For instance, in March 2020, Thermo Fisher Scientific extended its Dye-based SYBR Green real-time PCR (qPCR) portfolio with the launch of PowerTrack SYBR Green PCR Master Mix, which is a pre-formulated, universal, 2X concentration Master Mix for real-time PCR workflows with built-in visual dye-based indicators for accurate reaction set up.​

Additionally, due to the recent COVID-19 pandemic, there is a positive impact on the PCR Reagents market due to the increasing demand for the clinical diagnostic segment of the market. As the authorities have not recommended the viral culture tests, almost all the diagnostic tests use RT-PCR to test the population who have symptoms of COVID 19 and are advised by healthcare professionals to undergo a diagnostic test. For instance, in May 2020, Eurofins Technologies launched its CE-IVD marked real-time RT-PCR (polymerase chain reaction to reverse transcriptase chain reaction) multiplex for the direct qualitative detection of the pathogen of the new coronavirus (SARS-CoV-2).

North America Dominates the Market and the Region is Expected to Dominate during the Forecast Period

North America dominates the biotechnology reagents market and incurs the highest expenditure for global R&D. The North American segment is on the rise due to various ongoing research on biological sciences, an increase in the prevalence of cancer, chronic infectious and genetic conditions, considerable investments by various biotechnology companies, and the consistently increasing utilization of biotechnology reagents in the market. According to the estimates of Globocan 2020, there were around 195,499 new cases of cancer in Mexico. Approximately 90,222 deaths were recorded due to cancer in Mexico.

Furthermore, companies are either acquiring or merging with many companies for significant deals, and they are investing heavily in biotechnology and pharmaceutical research activities and also launching new products in the region. In April 2019, Quantabio, a US-based Biotech company, launched Qscript to 1-step, a lyophilized single-reaction reagent optimized for highly sensitive and reproducible RT-qPCR RNA applications.

Moreover, the recent COVID 19 pandemic has also spurred the demand for biotechnology reagents in the region due to the increasing case of COVID-19 infection. For instance, in June 2020, Galenvs Sciences Inc., a Montreal-based biotech firm, entered into an agreement Canadian Federal Government for the supply of functionalized magnetic reagents for Coronavirus RNA extraction necessary to enable the COVID-19 testing efforts across Canada. Thus, the market is expected to grow significantly in the North American region, during the forecast period.

Competitive Landscape

The biotechnology reagents market is highly competitive, with a good number of players. Companies like Abbott Laboratories, Agilent Technologies, Danaher Corp. (Beckman Coulter), Becton Dickinson & Company, Bio-Rad Laboratories, GE Healthcare, Siemens Healthcare, Merck KGaA (Sigma Aldrich Corporation), Thermo Fisher Scientific Inc., and Waters Corporation hold a substantial market share. Additionally, the key players have been involved in various strategic alliances such as acquisitions, collaborations, along with the launch of advanced products to secure the position in the global market. In July 2020, Tetramer Shop, based out of Denmark, and Polaris Biology, a Chinese biotech firm, entered into a partnership for the sale and distribution of MHC tetramer reagents developed by Tetramer Shop for T cell immune monitoring and antigen specificity profiling in China.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

ページTOPに戻る

Table of Contents

1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 High R&D Expenditure by Biotechnology Companies coupled with the Rise in Number of Biotechnology Firms
4.2.2 Increasing Interest in Stem Cell Research
4.2.3 Growing Burden of Cancer, Genetic Disorders, and Chronic Infectious Diseases
4.3 Market Restraints
4.3.1 Stringent Government Regulations for Approval of Reagents
4.3.2 High Cost of Reagents
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Technology
5.1.1 Life Science Reagents
5.1.1.1 PCR
5.1.1.2 Cell Culture
5.1.1.3 Hematology
5.1.1.4 In-vitro Diagnostics
5.1.1.5 Other Technologies
5.1.2 Analytical Reagents
5.1.2.1 Chromatography
5.1.2.2 Mass Spectrometry
5.1.2.3 Electrophoresis
5.1.2.4 Flow Cytometry
5.1.2.5 Other Analytical Reagentss
5.2 By Application
5.2.1 Protein Synthesis and Purification
5.2.2 Gene Expression
5.2.3 DNA and RNA Analysis
5.2.4 Drug Testing
5.2.5 Other Applications
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Agilent Technologies
6.1.3 Danaher Corporation (Beckman Coulter Inc.)
6.1.4 Becton Dickinson & Company
6.1.5 Bio-Rad Laboratories
6.1.6 bioMérieux SA
6.1.7 Siemens Healthcare
6.1.8 Merck KGaA (Sigma Aldrich Corporation)
6.1.9 Thermo Fisher Scientific Inc.
6.1.10 Waters Corporation
6.1.11 Eurofins Scientific
6.1.12 Takara Bio
6.1.13 QIAGEN NV
6.1.14 Illumina Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS